Latest News

Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Deupirfenidone 825 mg reduced 26-week FVC decline by 91.0 mL versus placebo in the phase 2b ELEVATE-IPF trial in idiopathic pulmonary fibrosis.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

The Fast Track designation adds to LTI-03's prior Orphan Drug status as Rein Therapeutics advances the Phase 2 RENEW trial in IPF.

Academic pulmonologists from Mass General, Duke, and Cleveland Clinic discuss biologic selection, mucus plugging, and more.

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.

The first-in-class D1 receptor antagonist earns Priority Review and Orphan Drug designation, with an FDA action date late in Q1 2027.

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

An international 35-expert Delphi panel reached consensus on 33 of 35 statements on precautionary allergen labelling reference doses.

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and improves care for skin of color.

Samir Parikh, MD, on the B-cell pathway in IgA nephropathy, biomarker gaps, treatment sequencing, and the case for earlier detection.

A FORWARD cohort study of 1,359 children found race, income, health literacy, and neighborhood deprivation each predicted food allergy resolution.

This week's highlight includes phase 3 trial results across dermatology, cardiology, and pulmonology, and a major conference preview.